Compton Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
– Sell
-2,530
Closed -$243K – 148
2018
Q3
$243K Sell
2,530
-50
-2% -$4.85K 0.1% 134
2018
Q2
$246K Buy
2,580
+110
+4% +$10.1K 0.1% 132
2018
Q1
$217K Buy
+2,470
New +$225K 0.09% 145

Other funds holding XBI

Compton Capital Management's XBI Position: Q4 2018 in Review

Compton Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2018, closing a stake of 2,530 shares — an estimated $243K sold.

Compton Capital Management first reported a position in XBI in Q1 2018 and held it in 3 quarters. The position peaked at $246K in Q2 2018. 427 funds tracked by Wall St. Rank hold XBI as of Q4 2018.

  • Compton Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2018 after selling out during the quarter.
  • Compton Capital Management sold 2,530 State Street SPDR S&P Biotech ETF shares in Q4 2018, an estimated $243K.
  • Compton Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2018 and held it in 3 quarters.
  • Compton Capital Management's State Street SPDR S&P Biotech ETF position peaked at $246K in Q2 2018.
  • 427 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2018.

Based on Compton Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.